James C. Hamilton
Known title: Chief Discovery/Trans MedicineCIK: 0001830755
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 10,000 | $750K | 4/23/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 10,000 | $642K | 3/5/2026 | View on chart |
| ARWR | ▲ Buy | Grant | 75,000 | $0 | 1/6/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 4,625 | $283K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 6,090 | $379K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 14,792 | $932K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 12,711 | $813K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,200 | $77K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 437 | $29K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 309 | $21K | 1/5/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 20,000 | $700K | 10/1/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 15,000 | $450K | 9/12/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 15,000 | $375K | 9/2/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 9,389 | $188K | 8/15/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 611 | $12K | 8/13/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 21,758 | $428K | 1/6/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 10,971 | $221K | 1/6/2025 | View on chart |
| ARWR | ▲ Buy | Grant | 100,000 | $0 | 1/4/2025 | View on chart |
| ARWR | ▼ Sell | Open Market | 6,000 | $168K | 4/1/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 4,238 | $155K | 1/12/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,702 | $138K | 1/12/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,800 | $61K | 1/5/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 8,000 | $280K | 1/5/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 12,343 | $440K | 1/5/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 10,000 | $350K | 1/5/2024 | View on chart |
| ARWR | ▲ Buy | Grant | 75,000 | $0 | 1/4/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,500 | $111K | 1/3/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,300 | $75K | 1/3/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 500 | $17K | 1/3/2024 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,000 | $107K | 6/30/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 7,230 | $270K | 1/5/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 6,573 | $246K | 1/5/2023 | View on chart |
| ARWR | ▲ Buy | Grant | 60,000 | $0 | 1/4/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,642 | $62K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,194 | $45K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,837 | $109K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 300 | $12K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 136 | $6K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 3,682 | $142K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 300 | $12K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 247 | $10K | 1/3/2023 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,290 | $139K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 2,100 | $130K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,100 | $69K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 700 | $45K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 60 | $4K | 1/5/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 500 | $35K | 1/4/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 9,955 | $646K | 1/4/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 7,469 | $490K | 1/4/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 802 | $54K | 1/4/2022 | View on chart |
| ARWR | ▼ Sell | Open Market | 649 | $44K | 1/4/2022 | View on chart |
| ARWR | ▲ Buy | Grant | 55,000 | $0 | 1/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.